https://scholars.lib.ntu.edu.tw/handle/123456789/633191
標題: | Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis | 作者: | Silverberg, Jonathan I Guttman-Yassky, Emma Thaçi, Diamant Irvine, Alan D Stein Gold, Linda Blauvelt, Andrew Simpson, Eric L CHIA-YU CHU et al., |
關鍵字: | Allergy/Immunology | Allergy/Immunology General | Clinical Medicine | Clinical Medicine General | Dermatology | Dermatology General | Inflammatory Disease | T-Cells | 公開日期: | 23-三月-2023 | 卷: | 388 | 期: | 12 | 來源出版物: | The New England journal of medicine | 摘要: | Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633191 | ISSN: | 00284793 | DOI: | 10.1056/NEJMoa2206714 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。